109 related articles for article (PubMed ID: 15477218)
61. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Pfeifer H; Wassmann B; Pavlova A; Wunderle L; Oldenburg J; Binckebanck A; Lange T; Hochhaus A; Wystub S; Brück P; Hoelzer D; Ottmann OG
Blood; 2007 Jul; 110(2):727-34. PubMed ID: 17405907
[TBL] [Abstract][Full Text] [Related]
62. Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
Leoni V; Biondi A
Haematologica; 2015 Mar; 100(3):295-9. PubMed ID: 25740105
[No Abstract] [Full Text] [Related]
63. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Wassmann B; Pfeifer H; Goekbuget N; Beelen DW; Beck J; Stelljes M; Bornhäuser M; Reichle A; Perz J; Haas R; Ganser A; Schmid M; Kanz L; Lenz G; Kaufmann M; Binckebanck A; Brück P; Reutzel R; Gschaidmeier H; Schwartz S; Hoelzer D; Ottmann OG
Blood; 2006 Sep; 108(5):1469-77. PubMed ID: 16638934
[TBL] [Abstract][Full Text] [Related]
64. Efficacy of imatinib mesylate (STI571) in conjunction with alpha-interferon: long-term quantitative molecular remission in relapsed P-190(BCR-ABL)-positive acute lymphoblastic leukemia.
Visani G; Isidori A; Malagola M; Alberti D; Capdeville R; Martinelli G; Piccaluga PP; Amabile M; Guiducci B; Tura S; Baccarani M
Leukemia; 2002 Oct; 16(10):2159-60. PubMed ID: 12357372
[No Abstract] [Full Text] [Related]
65. Combination of imatinib and established antileukemic treatment modalities for otherwise refractory BCR-ABL positive lymphoblastic leukemia.
Fruehauf S; Topaly J; Buss EC; Schad M; Goerner M; Zeller WJ; Ho AD
Haematologica; 2002 Dec; 87(12):ECR38. PubMed ID: 12495909
[No Abstract] [Full Text] [Related]
66. Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL.
Riva G; Luppi M; Lagreca I; Barozzi P; Quadrelli C; Vallerini D; Zanetti E; Basso S; Forghieri F; Morselli M; Maccaferri M; Paolini A; Fantuzzi V; Messerotti A; Maffei R; Iacobucci I; Martinelli G; Marasca R; Narni F; Comoli P; Potenza L
Br J Haematol; 2014 Jan; 164(2):299-302. PubMed ID: 24134676
[No Abstract] [Full Text] [Related]
67. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.
Towatari M; Yanada M; Usui N; Takeuchi J; Sugiura I; Takeuchi M; Yagasaki F; Kawai Y; Miyawaki S; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
Blood; 2004 Dec; 104(12):3507-12. PubMed ID: 15315963
[TBL] [Abstract][Full Text] [Related]
68. The first case of acute lymphoblastic leukemia with the e19a2 BCR-ABL1 transcript: imatinib therapy followed by unrelated donor transplantation induces a durable molecular response.
Jeon EK; Lim J; Kim M; Yahng SA; Lee SE; Cho BS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lee S
Leukemia; 2011 Feb; 25(2):366-7. PubMed ID: 21072049
[No Abstract] [Full Text] [Related]
69. [Application of imatinib in BCR- ABL positive acute lymphoblastic leukemia treatment in the real world].
Wan YL; Wang Y; Liu BC; Liu X; Gong XY; Zhao XL; Wang TY; Jiang EL; Feng SZ; Han MZ; Qiu LG; Mi YC; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):886-891. PubMed ID: 27801322
[TBL] [Abstract][Full Text] [Related]
70. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.
Boer JM; Koenders JE; van der Holt B; Exalto C; Sanders MA; Cornelissen JJ; Valk PJ; den Boer ML; Rijneveld AW
Haematologica; 2015 Jul; 100(7):e261-4. PubMed ID: 25769542
[No Abstract] [Full Text] [Related]
71. NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse.
Clarke S; O'Reilly J; Romeo G; Cooney J
Leuk Res; 2011 Jul; 35(7):e131-3. PubMed ID: 21489623
[No Abstract] [Full Text] [Related]
72. [Current chemotherapy of adult acute lymphoblastic leukemia].
Usui N
Rinsho Ketsueki; 2010 Oct; 51(10):1549-57. PubMed ID: 20962489
[No Abstract] [Full Text] [Related]
73. [Cell surface markers and treatment results in childhood acute lymphoblastic leukemia (ALL)].
Koizumi S; Tsurusawa M; Katano N
Rinsho Ketsueki; 1997 May; 38(5):389-92. PubMed ID: 9194381
[No Abstract] [Full Text] [Related]
74. [Pregnancy in acute lymphoid leukemia].
Pajor A; Zimonyi I
Orv Hetil; 1989 Mar; 130(12):621-4. PubMed ID: 2704549
[TBL] [Abstract][Full Text] [Related]
75. Acute lymphoblastic leukemia (ALL) and cancer procoagulant activity.
Pogliani EM; Lanzafame C; Bucciarelli P; Corneo G
Haematologica; 1991; 76(6):526-7. PubMed ID: 1688361
[No Abstract] [Full Text] [Related]
76. The U.S. trials in adult acute lymphoblastic leukemia.
Larson RA
Ann Hematol; 2004; 83 Suppl 1():S127-8. PubMed ID: 15124704
[No Abstract] [Full Text] [Related]
77. Importance of minimal residual disease testing during the second year of disease: still no answer?
Aricò M; Conter V; Valsecchi MG; Masera G
J Clin Oncol; 2003 Dec; 21(23):4463-4; author reply 4464-5. PubMed ID: 14645441
[No Abstract] [Full Text] [Related]
78. The prognostic significance of serum XCL1 concentration in patients with acute lymphoblastic leukemia: a pilot study.
Gutiérrez-Aguirre CH; Flores-Jiménez JA; Alatorre-Ricardo J; Cantú-Rodríguez OG; Rosas-Taraco A; Salazar-Riojas R; Jaime-Pérez JC; Sánchez-Cárdenas M; López-Silva L; Martínez-Castilla AM; Salinas-Carmona MC; Gómez-Almaguer D
Ann Hematol; 2017 Dec; 96(12):2015-2024. PubMed ID: 29027574
[TBL] [Abstract][Full Text] [Related]
79. Treatment of acute lymphoblastic leukaemia : a new era.
Apostolidou E; Swords R; Alvarado Y; Giles FJ
Drugs; 2007; 67(15):2153-71. PubMed ID: 17927282
[TBL] [Abstract][Full Text] [Related]
80. [Recent advances on molecular targets for treatment of acute leukemia].
Okuda T
Nihon Rinsho; 2007 Jan; 65 Suppl 1():128-35. PubMed ID: 17474403
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
